A Randomized, Double-blind, Placebo-controlled, Multicenter Long-term Safety and Tolerability Study of ETC-1002 in Patients With Hyperlipidemia at High Cardiovascular Risk Who Are Not Adequately Controlled by Their Lipid-Modifying Therapy

Trial Profile

A Randomized, Double-blind, Placebo-controlled, Multicenter Long-term Safety and Tolerability Study of ETC-1002 in Patients With Hyperlipidemia at High Cardiovascular Risk Who Are Not Adequately Controlled by Their Lipid-Modifying Therapy

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 23 Apr 2018

At a glance

  • Drugs Bempedoic acid (Primary)
  • Indications Atherosclerosis; Hyperlipoproteinaemia type IIa
  • Focus Adverse reactions; Registrational
  • Acronyms CLEAR Harmony
  • Sponsors Esperion Therapeutics
  • Most Recent Events

    • 20 Apr 2018 This trial has been completed in Poland (end date: 2018-02-21)
    • 13 Apr 2018 This trial has been completed in Netherlands (end date: 2018-02-21)
    • 26 Feb 2018 Planned End Date changed from 1 May 2018 to 31 Mar 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top